Adjuvant treatment of colon cancer

Current Opinion in Oncology

Volumn 17, Issue 4, 2005, Pages 381-385

  Bleiberg, Harry ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant; Cancer; Colon

Indexed keywords

5 FLUOROURACIL PLUS LEUCOVORIN; 5 FLUOROURACIL PLUS LEUCOVORIN PLUS OXALIPLATIN; 5 FLUOROURACIL PLUS LEVAMISOLE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; IRINOTECAN PLUS 5 FLUOROURACIL; LEVAMISOLE; OXALIPLATIN; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS;

EID: 21344435060     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000166648.92674.4c     Document Type: Review

References (29)

1. GLOBOCAN. Cancer Incidence, Mortality and Prevalence Worldwide. Version IARC CancerBase No. 5. Lyon: IARC Press; 2001.
2. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40:15-24.
3. American Joint Committee on Cancer. Cancer Staging Manual, edn 5. Philadelphia: Lippincott-Raven; 1998.
4. Carter SK. Large bowel cancer: the current status of treatment. J Natl Cancer Inst 1976; 56:3-10.
5. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1989; 259:3571-3578.
6. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 8:322-352.
7. International Multicentre Pooled Analysis of Colon Cancer Trials. (IMPACT) Investigators: efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-944.
8. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993; 11:1879-1887.
9. Francini G, Potrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106:899-906.
10. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-250.
11. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85:1437-1443.
12. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349-1355.
13. International Multicentre Pooled Analysis of B2 Colon Trials. (IMPACT B2) Investigators: efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356-1363.
14. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of post-operative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
15. Sakamoto J, Ohashi Y, Hamada C, et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484-492. This article gives a complete overview of what can be expected with oral fluoropyrimidines and offers a new paradigm for treating Dukes B cancer patients.
16. James RD, Donaldson D, Gray R, et al. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 2003; 90:1200-1212.
17. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360:671-677.
18. de Gramont A, Figer M, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
19. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
20. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351. This is the full report of the MOSAIC study comparing FOLFOX4 with LV5FU2 and showing a 23% decrease in the risk of relapse.
21. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
24. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 1997; 15:2432-2441.
25. Buyse M, Piedbois P. Should Dukes'B patients receive adjuvant therapy? a statistical perspective. Semin Oncol 2001; 28:20-24.
26. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-1571. Opens the way for using the genetic signature for identifying patients at risk of recurrence.
27. Garrity MM, Burgart U, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 over expression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22:1572-1582. Potential molecular markers for high-risk Dukes B patients.
28. Galizia G, Ferraraccio F, Lieto E, et al. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum 2004; 47:1904-1914. Another way to identify patients at high risk of recurrence.
29. Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004; 240: 624-628. Sentinel lymph node sampling in colon cancer is unlikely to improve risk stratification for resectable colon cancer.